- Home
- GOVX vs MTNB Comparison
GOVX vs MTNB Comparison
Compare GOVX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOVX | MTNB |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.6M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GOVX | MTNB |
|---|---|---|
| Price | $0.28 | $2.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 814.4K | 341.7K |
| Earning Date | 11-12-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,489,145.00 | $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.15 |
| 52 Week High | $157.50 | $3.16 |
Technical Indicators
Market Signals| Indicator | GOVX | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 23.04 | 74.24 |
| Support Level | N/A | $0.39 |
| Resistance Level | $0.46 | N/A |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 7.65 | 87.33 |
Price Performance
Historical ComparisonAbout GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.